Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436)

Basic

  • Market Cap

    CN¥134.76B

  • EV

    CN¥133.64B

  • Shares Out

    603.32M

  • Revenue

    CN¥10.03B

  • Employees

Margins

  • Gross

    33.81%

  • EBITDA

    34.28%

  • Operating

    33.81%

  • Pre-Tax

    33.55%

  • Net

    27.74%

  • FCF

Returns (5Yr Avg)

  • ROA

    13.16%

  • ROTA

    23.93%

  • ROE

    23.05%

  • ROCE

    25.71%

  • ROIC

    42.62%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    CN¥295.86

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    CN¥2,633.28M

  • Net Debt

    -CN¥1,664.77M

  • Debt/Equity

    0.07

  • EBIT/Interest

Growth (CAGR)

  • Rev 3Yr

    15.51%

  • Rev 5Yr

    16.06%

  • Rev 10Yr

    21.81%

  • Dil EPS 3Yr

    18.51%

  • Dil EPS 5Yr

    19.52%

  • Dil EPS 10Yr

    19.59%

  • Rev Fwd 2Yr

    15.31%

  • EBITDA Fwd 2Yr

    18.19%

  • EPS Fwd 2Yr

    23.61%

  • EPS LT Growth Est

    19.88%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

    20.32%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

Revenues

5,705.9

6,492.5

8,004.3

8,674.5

10,034.6

Other Revenues, Total

16.3

18.3

17.3

19.5

Total Revenues

5,722.3

6,510.8

8,021.6

8,694

10,034.6

Total Revenues % Chg.

20.1%

13.8%

23.2%

8.4%

15.4%

Cost of Goods Sold, Total

3,198.4

3,584.3

3,968

4,734.9

6,642.2

Gross Profit

2,523.8

2,926.5

4,053.6

3,959.1

3,392.5

Selling General & Admin Expenses, Total

796.2

982.2

1,027.2

814.4

Provision for Bad Debts

2.8

1.9

7.1

-6.8

R&D Expenses

119.4

97.6

199.5

230

Other Operating Expenses

45.9

53.2

72.1

72

Other Operating Expenses, Total

964.3

1,134.9

1,305.9

1,109.6

Operating Income

1,559.5

1,791.6

2,747.7

2,849.5

3,392.5

Interest Expense, Total

-31.1

-27.4

-32.9

-38

Interest And Investment Income

95.3

149.3

144.5

171.6

Net Interest Expenses

64.2

121.9

111.6

133.6

Currency Exchange Gains (Loss)

4.7

-3.3

-3.3

7.2

Other Non Operating Income (Expenses)

-2.7

-4.4

-21.6

-36.5

-25.8

EBT, Excl. Unusual Items

1,625.7

1,905.8

2,834.4

2,953.8

3,366.6

Impairment of Goodwill

-6.1

Gain (Loss) On Sale Of Investments

-0

6.7

4.5

-0

Gain (Loss) On Sale Of Assets

4.6

40.3

27.6

10

Asset Writedown

-1

-0.3

Other Unusual Items

20.4

26.1

3.6

14.3

EBT, Incl. Unusual Items

1,644.6

1,978.9

2,869

2,977.7

3,366.6

Income Tax Expense

257.7

289.5

404.2

454.8

582.9

Earnings From Continuing Operations

1,386.9

1,689.4

2,464.8

2,523

2,783.7

Minority Interest

-12.6

-17.8

-32.9

-50.6

Net Income

1,374.4

1,671.5

2,431.9

2,472.3

2,783.7

Net Income to Common Incl Extra Items

1,374.4

1,671.5

2,431.9

2,472.3

2,783.7

Net Income to Common Excl. Extra Items

1,374.4

1,671.5

2,431.9

2,472.3

2,783.7

Total Shares Outstanding

603.3

603.3

603.3

603.3

603.3

Weighted Avg. Shares Outstanding

602.8

603.4

603.4

603

603.8

Weighted Avg. Shares Outstanding Dil

602.8

603.4

603.4

603

603.8

EPS

2.3

2.8

4

4.1

4.6

EPS Diluted

2.3

2.8

4

4.1

4.6

EBITDA

1,615.4

1,881.8

2,853.9

2,896.8

3,439.8